Researchers have found a way to better control the preclinical generation of key neurons depleted in Parkinson's disease, pointing toward a new approach for a disease with no cure and few effective treatments.
Although there are still some aspects pending confirmation for its use in the clinical setting, and its resolution needs to be improved slightly, a study has shown that a method routinely used to carry out ophthalmological tests can also be used to monitor the neurodegeneration that occurs in Parkinson's patients. In the course of the research it was found that the neurodegeneration of the retina probably precedes cognitive impairment.
Researchers have used artificial intelligence techniques to massively accelerate the search for Parkinson's disease treatments. The researchers designed and used an AI-based strategy to identify compounds that block the clumping, or aggregation, of alpha-synuclein, the protein that characterises Parkinson's.
A new study offers a first look into the complex molecular changes that occur in brain cells with Lewy bodies, which are key pathological hallmarks of Parkinson's disease and some dementias. The findings reveal that brain cells with Lewy bodies exhibit a specific gene expression pattern akin to a disease-related fingerprint.
